Ifosfamide in advanced carcinoma of the esophagus: A phase II trial with severe toxicity

S. M. Ansell, A. S. Alberts, G. Falkson

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for urprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number3
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Ifosfamide in advanced carcinoma of the esophagus: A phase II trial with severe toxicity'. Together they form a unique fingerprint.

Cite this